Center for Musculoskeletal Research, Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, United States.
Elife. 2019 May 24;8:e45342. doi: 10.7554/eLife.45342.
Identification of pro-regenerative approaches to improve tendon healing is critically important as the fibrotic healing response impairs physical function. In the present study we tested the hypothesis that S100a4 haploinsufficiency or inhibition of S100a4 signaling improves tendon function following acute injury and surgical repair in a murine model. We demonstrate that S100a4 drives fibrotic tendon healing primarily through a cell non-autonomous process, with S100a4 haploinsufficiency promoting regenerative tendon healing. Moreover, inhibition of S100a4 signaling via antagonism of its putative receptor, RAGE, also decreases scar formation. Mechanistically, S100a4 haploinsufficiency decreases myofibroblast and macrophage content at the site of injury, with both cell populations being key drivers of fibrotic progression. Moreover, S100a4-lineage cells become α-SMA myofibroblasts, via loss of S100a4 expression. Using a combination of genetic mouse models, small molecule inhibitors and in vitro studies we have defined S100a4 as a novel, promising therapeutic candidate to improve tendon function after acute injury.
鉴定促进肌腱愈合的前再生方法至关重要,因为纤维性愈合反应会损害身体功能。在本研究中,我们测试了以下假设:S100a4 单倍不足或抑制 S100a4 信号转导可改善小鼠模型中急性损伤和手术修复后的肌腱功能。我们证明,S100a4 主要通过非细胞自主过程驱动纤维性肌腱愈合,S100a4 单倍不足可促进再生性肌腱愈合。此外,通过拮抗其假定的受体 RAGE 抑制 S100a4 信号转导也可减少疤痕形成。从机制上讲,S100a4 单倍不足可减少损伤部位的肌成纤维细胞和巨噬细胞含量,这两种细胞群都是纤维化进展的关键驱动因素。此外,S100a4 谱系细胞通过 S100a4 表达的丧失成为 α-SMA 肌成纤维细胞。通过使用遗传小鼠模型、小分子抑制剂和体外研究,我们将 S100a4 定义为一种新的、有前途的治疗候选药物,可改善急性损伤后的肌腱功能。
Am J Physiol Lung Cell Mol Physiol. 2021-5-1
J Biol Chem. 2024-6
FASEB Bioadv. 2025-4-3
Matrix Biol Plus. 2025-2-15
bioRxiv. 2024-11-14
NPJ Regen Med. 2024-10-17
Front Immunol. 2018-8-6
J Vis Exp. 2016-9-19
Immunity. 2016-3-15
J Appl Physiol (1985). 2015-9-1
J Hepatol. 2014-8-9